28,142 Shares in Organon & Co. (NYSE:OGN) Purchased by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC acquired a new position in Organon & Co. (NYSE:OGN) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 28,142 shares of the company’s stock, valued at approximately $538,000.

Several other hedge funds have also recently bought and sold shares of OGN. Prospera Private Wealth LLC purchased a new stake in Organon & Co. in the 3rd quarter worth about $25,000. William B. Walkup & Associates Inc. purchased a new stake in Organon & Co. in the 2nd quarter worth about $31,000. Abich Financial Wealth Management LLC lifted its stake in Organon & Co. by 5,646.3% in the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares in the last quarter. Atlas Capital Advisors LLC lifted its stake in Organon & Co. by 2,236.5% in the 2nd quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after acquiring an additional 2,147 shares in the last quarter. Finally, Trust Co. of Vermont lifted its stake in Organon & Co. by 109.4% in the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock worth $50,000 after acquiring an additional 1,372 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

Shares of OGN stock opened at $15.11 on Wednesday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a fifty-two week low of $10.97 and a fifty-two week high of $23.10. The stock’s 50-day moving average is $16.64 and its two-hundred day moving average is $19.28. The firm has a market cap of $3.89 billion, a P/E ratio of 3.00, a PEG ratio of 0.71 and a beta of 0.75.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.78 EPS. Analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.41%. The ex-dividend date is Tuesday, November 12th. Organon & Co.’s dividend payout ratio is 22.22%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the stock from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.